Updated Jul 16, 2026
Gheuens Sarah has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $962K.
Sarah Gheuens is the Chief Medical Officer at Agios Pharmaceuticals, Inc., where she focuses on developing medicines for rare diseases. She has also held a similar role at Viridian Therapeutics, Inc.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale | 4.0K | $37.56 | $151K |
| 2026-07-02 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise | 8.4K | $0.00 | |
| 2026-04-06 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 2.9K | $34.71 | $102K |
| 2026-04-06 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 8.5K | $0.00 | |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 1.2K | $28.96 | $34K |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 4.0K | $0.00 | |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 1.7K | $28.96 | $49K |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 5.7K | $0.00 | |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 1.2K | $28.96 | $34K |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 4.0K | $0.00 | |
| 2025-07-09 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale | 847 | $38.76 | $33K |
| 2025-07-09 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale | 11.1K | $37.93 | $420K |
| 2025-07-09 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise | 11.9K | $25.01 | $298K |
| 2025-07-01 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale | 4.1K | $34.17 | $140K |
| 2025-07-01 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise | 8.4K | $0.00 |
Sarah Gheuens is the Chief Medical Officer at Agios Pharmaceuticals, Inc., where she focuses on developing medicines for rare diseases. She has also held a similar role at Viridian Therapeutics, Inc.…
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 8 open-market sales ($962K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Gheuens Sarah profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.